CANCER DISCOVERY

CONTENTS

OCTOBER 2011
VOLUME 1
NUMBER 5

IN THIS ISSUE	Highlighted research articles viii
NEWS IN BRIEF	Important news stories affecting the community
NEWS IN DEPTH	Q&A: Phillip Sharp on Biomedical Convergence370
	Drugs, Diagnostic Tests Approved Quickly371
	Speed Traps for Trials372
RESEARCH WATCH	Selected highlights of recent articles of exceptional significance from the cancer literature
VIEWS	In The Spotlight
	The Prospects of HPV Vaccination in Cervical Cancer Prevention: Results of a New Independent Trial 377 F.X. Bosch, S. de Sanjose, and X. Castellsague Commentary on Herrero et al., p. 408
	Nuclear Receptor LXR as a Novel Therapeutic Antitumoral Target in Glioblastoma

Prospective

Forty Years of Translational Cancer Research......383 WN Hait

REVIEW

The Emergence of IncRNAs in Cancer Biology391 J.R. Prensner and A.M. Chinnaiyan

RESEARCH Prevention of Persistent Human ARTICLES Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica......408


> R. Herrero, S. Wacholder, A.C. Rodríguez, D. Solomon, P. González, A.R. Kreimer, C. Porras, J. Schussler, S. Jiménez, M.E. Sherman, W. Quint, J.T. Schiller, D.R. Lowy, M. Schiffman, and A. Hildesheim for the Costa Rica Vaccine Trial Group

Précis: Cervical cancer prevention efforts in developing countries should focus on vaccination of young women prior to sexual activity.


Variants in Inflammation Genes Are Implicated in Risk of Lung Cancer in Never Smokers Exposed to Second-hand Smoke 420

M.R. Spitz, I.P. Gorlov, C.I. Amos, Q. Dong, W. Chen, C.J. Etzel, O.Y. Gorlova, D.W. Chang, X. Pu, D. Zhang, L. Wang, J.M. Cunningham, P. Yang, and X. Wu


Précis: A variant of the TGF-β receptor ACVR1B increases risk of NSCLC in never smokers exposed to environmental tobacco smoke.











S.V. Novitskiy, M.W. Pickup, A.E. Gorska, P. Owens, A. Chytil, M. Aakre, H. Wu, Y. Shyr, and H.L. Moses

Précis: IL-17 contributes to immune evasion in TGF- β receptor II-deficient tumors and represents a novel therapeutic target.

D. Guo, F. Reinitz, M. Youssef, C. Hong, D. Nathanson, D. Akhavan, D. Kuga, A.N. Amzajerdi, H. Soto, S. Zhu, I. Babic, K. Tanaka, J. Dang, A. Iwanami, B. Gini, J. DeJesus, D.D. Lisiero, T.T. Huang, R.M. Prins, P.Y. Wen, H.I. Robins, M.D. Prados, L.M. DeAngelis, I.K. Mellinghoff, M.P. Mehta, C.D. James, A. Chakravarti, T.F. Cloughesy, P. Tontonoz, and P.S. Mischel

Précis: Inhibition of cholesterol metabolism is a novel therapeutic strategy for *EGFR*-mutant glioblastomas.

ON THE COVER

Herrero and colleagues demonstrate that Cervarix, a bivalent ASO4-adjuvanted HPV16/18 vaccine, is over 90% effective in preventing persistent infection in HPV-negative women among a large Costa Rican population with a high incidence of cervical cancer, but its efficacy diminishes with age and sexual experience. One of the first public HPV vaccine trials, this study underscores the importance of early HPV vaccination in cervical cancer prevention, particularly in developing countries. For details, please see the article by Herrero and colleagues on page 408.



CANCER DISCOVERY

1 (5)

Cancer Discovery 2011;1:367-456.

Updated version Access the most recent version of this article at:

http://cancerdiscovery.aacrjournals.org/content/1/5

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications

Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link

http://cancerdiscovery.aacrjournals.org/content/1/5.

Click on "Request Permissions" which will take you to the Copyright Clearance Center's

(CCC)

Rightslink site.